Atux Iskay Group

Atux Iskay Group is a private U.S. biotech company developing small-molecule activators and modulators of Protein phosphatase 2A (PP2A). The company positions PP2A normalization as a broad therapeutic strategy across oncology, neurodegenerative disease, and respiratory disease, and describes its approach as potentially senotherapeutic. Its disclosed lead and named programs include ATUX-1215 and additional PP2A activator candidates for Alzheimer's disease, neuroblastoma, and pulmonary indications such as idiopathic pulmonary fibrosis. Atux Iskay also collaborates with academic researchers and provides public-domain PP2A activator compounds to support external research and publication. Available evidence indicates the company remains private, grant-funded, and preclinical, with NIH/SBIR support forming a meaningful part of its development base.